Daily weight loss pill achieves main goal in late-stage trial
Experimental weight loss pill clears its latest trial
- Eli Lilly's experimental GLP-1 pill, orforglipron, helped overweight adults with type 2 diabetes shed 10.5 per cent of their body weight in a late-stage trial.
- The once-daily pill also enabled 75 per cent of patients on the highest dose to lower their A1C level to 6.5 per cent or below, meeting a key diabetes management target.
- Orforglipron is a small-molecule pill, making it easier to manufacture and package than popular injectable GLP-1 drugs like Lilly's Zepbound and Novo Nordisk's Wegovy.
- In the 72-week study of over 1,600 participants, the 36-milligram dose led to an average weight loss of approximately 10.43 kg, significantly more than the placebo group.
- While side effects such as nausea and vomiting were reported, similar to previous trials, Lilly now has the full clinical data required to begin filing for regulatory approvals.